High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis [PDF]
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018 We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays.
Allan G. Kermode +2 more
exaly +6 more sources
John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis. [PDF]
DiseasesProgressive Multifocal Leukoencephalopathy (PML) is a possibly fatal demyelinating disease and John Cunningham Polyomavirus (JCPyV) is believed to cause this condition.
Mouliou DS.
europepmc +4 more sources
COS-7-based model: methodological approach to study John Cunningham virus replication cycle. [PDF]
Virol J, 2018 John Cunningham virus (JCV) is a human neurotropic polyomavirus whose replication in the Central Nervous System (SNC) induces the fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML).
Prezioso C +6 more
europepmc +6 more sources
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study. [PDF]
Brain Behav, 2019 Introduction Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab‐treated multiple sclerosis (MS) patients.
Auer M +7 more
europepmc +5 more sources
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. [PDF]
Ther Clin Risk Manag, 2014 Roberta Lanzillo,1 Raffaele Liuzzi,2 Luca Vallefuoco,3 Marcello Moccia,1 Luca Amato,1 Giovanni Vacca,1 Veria Vacchiano,1 Giuseppe Portella,3 Vincenzo Brescia Morra1 1Neurological Sciences Department, Federico II University, 2Institute of Biostructure and
Lanzillo R +8 more
europepmc +8 more sources
JAMA NeurologyThis cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.
Mariet C. Feltkamp +2 more
exaly +4 more sources
Progressive multifocal leukoencephalopathy successfully treated with mefloquine and literature review [PDF]
Encephalitis, 2021 Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection due to reactivation of John Cunningham virus (JCV). The diagnosis depends on evidence from clinical, imaging, and virologic studies.
Sungjoon Yoon +3 more
doaj +1 more source
Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns [PDF]
European Journal of NeurologyChris Dwyer +2 more
exaly +2 more sources
Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica. [PDF]
Epidemiology and Health, 2018 Yara Dadalti Fragoso +2 more
exaly +2 more sources
Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023 Objectives The primary objective was to evaluate long-term treatment persistence and safety of natalizumab in Finnish multiple sclerosis patients. The secondary objectives were to assess patient characteristics, use of natalizumab-related safety protocol,
Auli Verkkoniemi-Ahola +8 more
doaj +1 more source